New bispecific antibody YKST02 enters human trials for Hard-to-Treat myeloma
NCT ID NCT06574568
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing a new drug called YKST02 in 70 people with multiple myeloma that has relapsed or not responded to at least two prior treatments. YKST02 is a bispecific antibody designed to attach to both myeloma cells and immune cells, helping the immune system attack the cancer. The main goals are to check the drug's safety, find the right dose, and get an early look at whether it shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YKST02 (a bispecific antibody that targets BCMA on myeloma cells and CD3 on immune cells to help the body fight the cancer)
What this could lead to
If this early trial shows YKST02 is safe and effective, it could lead to a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is a very early Phase 1 study with only 70 participants, so the drug may not work or could have serious side effects. It is too soon to know if it will be better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Zhongshan Hospital of Dalian University
RECRUITINGDalian, Liaoning, 116001, China
Contact
Contact
-
Beijing Chao-yang Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100024, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Beijing Jishuitan Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100035, China
Contact
-
Guangxi Medical University Cancer Hospital
NOT_YET_RECRUITINGNanning, Guangxi, 530021, China
Contact
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, 150081, China
Contact
-
Henan Cancer Hospital
NOT_YET_RECRUITINGZhengzhou, Henan, 450003, China
Contact
-
Shandong Cancer Hospital
NOT_YET_RECRUITINGJinan, Shandong, 250117, China
Contact
Contact
-
Shanxi Cancer hospital
NOT_YET_RECRUITINGTaiyuan, Shanxi, 030013, China
Contact
-
Shunde Hospital of Southern Medical University
RECRUITINGFoshan, Guangdong, 528308, China
Contact
-
Sun Yat-sen Memorial Hospital
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510289, China
Contact
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact